Editorial: Advancements in diversity and drug resistance mechanisms in mycobacterial diseases
and adaptable microbial adversaries. In 2024, the disease claimed an estimated 1.23 million 16 lives, a stark statistic for a condition that is both preventable and curable (Organization 2025).The COVID-19 pandemic further strained diagnostic and treatment services, reversing hard-won 18 progress and highlighting the fragility of our healthcare defenses (Williams 2024). This
Authors
- Svetlana F. Khaiboullina (ORCID: https://orcid.org/0000-0002-5064-570X)
- Samira Tarashi (ORCID: https://orcid.org/0000-0002-7141-322X)
- Majid Marjani
- Manoj Baranwal
Institutions
- Pasteur Institute of Iran (IR)
- University of Nevada, Reno (US)
- Thapar Institute of Engineering & Technology (IN)
- Masih Daneshvari Hospital (IR)
Publication Details
- Journal
- Frontiers in Microbiology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3389/fmicb.2026.1812182
- Primary Topic
- Mycobacterium research and diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00